See Asscoiations below
|I CDX2||colorectal carcinoma|
|I CHROGRAN||chromogranin A|
|I CK19*||cytokeratin 19|
|I CK8/18||cytokeratin 8/18, adenocarcinoma|
|I ERA||epithelial related antigen (MOC-31)|
|I EBER ISH**||Epstein-Barr virus by CISH|
|I NSE||neuron-specific enolase (NSE)|
|I TTF1||thyroid transcription factor-1|
* indicates performed by affiliate laboratory
** in-situ hybridization
Technical component (TC) available for all markers.
Surgical samples received in 10% neutral buffered formalin
Formalin fixed paraffin embedded tissue
Previously prepared pathology materials (slides,smears, blocks or other samples)
Send reports, history and differential diagnosis
In extreme hot weather, ship with a cool pack
Marker and tissue specific
Results are reviewed by a board-certified pathologist to determine if tissues are positive or negative for the marker. These results may be used to assist in determining appropriate patient therapy or treatment. Immunohistochemistry combines the principles of histochemistry with the high degree of molecular specificity of the antibody-antigen reaction. The use of an enhanced-polymer detection system provides many benefits, including increased sensitivity, fewer procedural steps as compared to conventional techniques, and a reduction in non-specific background staining. MPLN offers a range of markers by Immunohistochemistry including hematologic, tissue specific, infectious agents and proliferation antigens.
Battifora et al. (1993). Appl Immunohistochem. 1:39-45.
Perttschuk et al. (1996). Cancer. 77:2514-15.
Press M et al. (2002). Steroids. 67:799-813